<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833712</url>
  </required_header>
  <id_info>
    <org_study_id>517/17.9.2020</org_study_id>
    <nct_id>NCT04833712</nct_id>
  </id_info>
  <brief_title>Stereotactic Radioablation for the Treatment of Refractory Atrial Fibrillation</brief_title>
  <acronym>RAD-AF</acronym>
  <official_title>Stereotactic Radioablation for the Treatment of Refractory Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the short-term (3 months) and intermediate-term (12 months)&#xD;
      safety and preliminary efficacy of stereotactic radiotherapy for pulmonary vein isolation to&#xD;
      treat refractory atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Current guidelines&#xD;
      recommend catheter ablation of AF in symptomatic patients refractory to antiarrhythmic&#xD;
      therapy. Pulmonary vein isolation (PVI) remains the cornerstone of any ablation procedure&#xD;
      irrespective of patient characteristics. Recently, single fraction stereotactic radioablation&#xD;
      has been used in patients with ventricular arrhythmias non-eligible for transcatheter&#xD;
      ablation or after a failed transcatheter ablation.&#xD;
&#xD;
      This is a single center, single arm, prospective and phase 1 clinical trial. Patients with&#xD;
      refractory AF non-eligible for transcatheter ablation or after a failed transcatheter&#xD;
      ablation will receive stereotactic radioablation for PVI.&#xD;
&#xD;
      The target contours for paroxysmal AF stereotactic radioablation will cover the left&#xD;
      atrial-venous wall, the myocardium and the myocardial sleeves of the PVs transmural at the PV&#xD;
      antrum, similar to catheter ablation. The contours will be approximately 4-6 mm wide along&#xD;
      the PVs / LA and approximately 2-4 mm deep depending on the tissue thickness.&#xD;
&#xD;
      A pre-validation study will evaluate the location with respect to right and left PVs.&#xD;
      Patients with esophagus in direct contact with the actual target lesion will be excluded.&#xD;
&#xD;
      PVI will be assessed by means of Cardio Insight non invasive mapping system during&#xD;
      radioablation.&#xD;
&#xD;
      Safety is the primary endpoint of the study. Safety will be assessed by incidence and&#xD;
      evaluation of any serious adverse evens using CTCAE V5.0 criteria associated with the&#xD;
      procedure through 90 days (short-term) and 12 months (intermediate term).&#xD;
&#xD;
      Efficacy will be evaluated by assessing atrial fibrillation recurrence and AF burden after 90&#xD;
      days of blank period until 12 months post-treatment based on pacemaker interrogation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 10, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90 days adverse events by CTCA5</measure>
    <time_frame>90 days</time_frame>
    <description>Safety will be assessed by incidence and evaluation of any adverse events using CTCA5 V5.0 criteria that are related to the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 months adverse events by CTCA5</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be assessed by incidence and evaluation of any adverse events using CTCA5 V5.0 criteria that are related to the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of atrial fibrillation after 90 days blanking period post-treatment</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation burden reduction after 90 days blanking period post-treatment</measure>
    <time_frame>90 days to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Arrythmia</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Stereotactic Radioablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Noninvasive Stereotactic Radioablation will be delivered in a single fraction to electrical isolate the pulmonary veins under CT-guidance.&#xD;
Pulmonary vein isolation will be assessed by using Cardioinsight non-invasive mapping system</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radioablation</intervention_name>
    <description>Stereotactic Radioablation targets on the pulmonary vein ostium aiming to achieve PVI</description>
    <arm_group_label>Stereotactic Radioablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 65-89&#xD;
&#xD;
          -  Paroxysmal or persistent symptomatic AF refractory to antiarrhythmic drugs.&#xD;
&#xD;
          -  Failure from the previous catheter ablation of AF, or contraindicate /unwilling to&#xD;
             undergo catheter ablation.&#xD;
&#xD;
          -  Dual chamber pacemaker implanted&#xD;
&#xD;
          -  Understands the nature of the study, treatment procedure and provides written informed&#xD;
             consent&#xD;
&#xD;
          -  Willing to comply with specified pre-, post- and follow-up testing, evaluations and&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Permanent AF&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Presence of any disease that is likely to shorten life expectancy to &lt; 1 year&#xD;
&#xD;
          -  Any cardiac surgery within three months prior to enrolment&#xD;
&#xD;
          -  Awaiting cardiac transplantation or other cardiac surgery within the next year&#xD;
&#xD;
          -  Myocardial infarction (MI) within 60 days prior to enrolment&#xD;
&#xD;
          -  Contraindications to oral anticoagulation&#xD;
&#xD;
          -  Active systemic infection or sepsis&#xD;
&#xD;
          -  History of a documented thromboembolic event such as stroke or transient ischemic&#xD;
             neurological attack (TIA) in the three months prior to enrollment.&#xD;
&#xD;
          -  Any other clinical condition that might jeopardize patient safety during participation&#xD;
             in this trial or prevent the subject from adhering to the trialprotocol&#xD;
&#xD;
          -  Esophageal ulcer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Spyridon Deftereos, MD, PhD</last_name>
    <phone>+30-2105832352</phone>
    <email>spdeftereos@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Chaïdári</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spyridon Deftereos, MD, PhD</last_name>
      <email>spdeftereos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Spyridon Deftereos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasilios Kouloulias, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mediterraneo Hospital</name>
      <address>
        <city>Glyfáda</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Spyridon Deftereos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>AF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

